Letairis

Active Ingredient(s): Ambrisentan
FDA Approved: * June 15, 2007
Pharm Company: * GILEAD
Category: Blood Pressure

Ambrisentan (U.S. trade name Letairis; E.U. trade name Volibris; India trade name Pulmonext by MSN labs) is a drug indicated for use in the treatment of pulmonary hypertension.[1][2] The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA).[3] Ambrisentan significantly improved e... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
3 Discussions